Clinical Trial Update: CP-675,206 In Patients With Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CP-675,206 in patients with advanced malignant melanoma has completed. The trial was sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CP-675,206

Snippet

Sponsor: AstraZeneca | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED